END-TO-END SOLUTION
In Vitro
Antibody Discovery
The challenges of
In Vitro Antibody Discovery
The abundance vs. affinity trap
Traditional screening samples a tiny fraction of a library, causing teams to miss rare, high-affinity binders. Even with NGS, relying on static frequency often mistakes fast-growing passenger clones for actual target binders.
Late-Stage Developability Failures
Strong binders frequently fail late in development due to unseen physicochemical weaknesses. Unflagged sequence liabilities cause costly downstream aggregation, loss of potency, and immunogenicity.
Fragmented Toolchains
Discovery teams rely on fragmented toolchains—command-line aligners, spreadsheets, and isolated scripts. These disconnected silos compromise data provenance, making reproducible analysis nearly impossible.
Lack of Clonal Diversity
Selecting abundant clones often yields nearly identical sequences. If that single antibody family fails wet-lab testing, the entire campaign fails. Sifting through millions of reads to find structurally diverse candidates is notoriously difficult.
From raw reads
to confident leads.
Replace disconnected scripts with a single, governed environment. Platforma seamlessly processes millions of NGS reads across selection rounds to track enrichment, flag liabilities early, and cluster distinct clonotypes. Move from raw data to a diverse, high-confidence panel of candidates.
The In Vitro analysis suite.
Antibody space
Visualize the entire discovery campaign. Map millions of antibodies in a unified UMAP space to compare conditions, identify enriched clusters, and spot diversity blindspots instantly.
Antibody clustering
Group sequences into distinct functional families. Guarantee structural diversity in your lead panel by avoiding redundant clonotypes.
Enrichment analysis
Track selection dynamics with precision. Calculate fold-change across successive panning rounds to confidently differentiate high-affinity target binders from fast-growing passenger clones.
Liabilities
Flag developability risks before costly wet-lab validation. Automatically annotate critical liabilities directly on the sequence.
Lead prioritization
Triangulate your best hits. Integrate enrichment scores, liability flags, clustering data into a unified workspace for confident decision-making.
Structure modeling
Move beyond sequence-only analysis. Generate high-quality 3D antibody models to assess paratope surfaces and support structure-informed downstream validation.
Reproducible workflows
Standardize your discovery pipelines. Deploy white-box, auditable workflows that ensure data provenance and scalability.
End-to-end workflow.
Data input & annotation
NGS of VHH, scFv, Fab display libraries
Multiple enrichment arms, negative controls
Powered by the industry-standard MiXCR engine
Clonotype clustering
Versatile clustering to group distinct families
Group by CDRs, FRs, and full length sequences
Powered by the industry-standard MMSeqs2 engine
Enrichment analysis
Track frequency changes across rounds
Identify binders and rescuers versus parasites
Include negative control to track antigen specific clones
De-risking
Configure liability flags in FRs and CDRs
Assess structural liabilities
Integrate functional assay data
Candidate prioritization
Integrate enrichment scores, liability flags, clustering data
Visualize entire repertoire on interactive map
Triangulate best hits